Cosmos Health will launch Sky Premium Life nutritional supplement products in Germany and Austria via Amazon and Ebay

CHICAGO, IL / ACCESSWIRE / September 15, 2022 / Cosmos Holdings d/b/a Cosmos Health, Inc. (“the company”) (Nasdaq: COSM), is a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, over-the-counter drugs and medical devices, today announced that the company’s proprietary line of nutraceuticals, Sky Premium Life, has entered into an exclusive agreement with Mediprovita GbR. Mediprovita will start selling its Sky Premium Life (“SPL”) products in Germany and Austria from the fourth quarter. The initial order of 20 SKUs will be sold through Amazon, Ebay, and Mediprovita’s e-commerce website. The Company plans to expand its relationship with Mediprovita in the near future to include the distribution of 70 SKUs.

Mediprovita is a full-service distributor and logistics provider of consumer products with over 30 years of experience. Cosmos has signed a distribution agreement with Mediprovita to be their exclusive distributor in Germany and Austria of the Sky Premium Life range. An exclusive brand of luxury, high quality nutritional supplements, with a full line of vitamins, minerals, herbs and unique formulas. Under the terms of the agreement, Mediprovita will use its sales, marketing and e-commerce expertise to distribute Sky Premium Life products throughout Germany and Austria. Aggelos Kiriazis, CEO of Mediprovita, said: “Sky Premium Life products are a perfect fit for our business, as we started selling dietary supplements two years ago with great success. Based on our extensive market research, we expect SPL products to have a strong acceptance rate. on the German and Austrian markets.”

“Our entry into Germany and Austria is an important step for us, as Germany has the largest market for nutraceuticals in Europe.” said Greg Siokas, chief executive of Cosmos Health. “We are continuing with our global rollout strategy by launching our products worldwide. So far in 2022, we have successfully introduced our products on Amazon in the US, UK, Canada and Singapore. Our Our primary focus remains to expand internationally, as we continue to leverage our strong global logistics and distribution capabilities, while expanding our customer base worldwide.”

According to Mordor Intelligence, the European nutraceuticals market is expected to grow at a CAGR of 7.5% to exceed $100 billion by 2027. Germany has the largest nutraceuticals market in Europe with around 14%. Market expansion in Europe is attributed to the continued rise in healthcare costs and an aging population.

About Cosmos Health, Inc.

Cosmos Health Inc. (Nasdaq: COSM) is a global healthcare group incorporated in 2009 and headquartered in Chicago, Illinois. Cosmos Health is engaged in the nutraceutical sector through its own exclusive product lines “Sky Premium Life” and “Mediterranation”. Additionally, the Company operates in the pharmaceutical sector through the provision of a wide range of branded generics and over-the-counter drugs and is involved in the healthcare distribution sector through its subsidiaries in Greece and the UK serving retail pharmacies and wholesale distributors. Cosmos Health is strategically focused on the R&D of novel patented nutraceuticals (PIs) and specialty root extracts as well as the R&D of proprietary complex generics and innovative OTC products. Cosmos has developed a global distribution platform and is currently expanding across Europe, Asia and North America. Cosmos Health has offices and distribution centers in Thessaloniki and Athens, Greece, and Harlow, UK. More information is available at and

Forward-looking statements

Except for historical information contained in this press release, matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act. of 1934. , as amended. Statements preceded by, followed by or which otherwise include the words “believes”, “expects”, “anticipates”, “intends”, “projects”, “estimates”, “plans” and expressions similar or future or conditional verbs such as “shall”, “should”, “should”, “may” and “could”, are generally forward-looking in nature and not historical facts, although all forward-looking statements do not include not the above. These statements involve unknown risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons beyond the Company’s control, including, but not limited to, the Company’s ability to raise sufficient funding to implement its business plans, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company’s business, operations and economy generally, and the ability to the Company to successfully develop and market its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s filings with the SEC, which are available on the SEC’s website ( The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact with Investor Relations:
Lytham Partners, LLC
Ben Chamsyan
Email: [email protected]
Such. : 646-829-9701

THE SOURCE: Cosmos Holdings, Inc.

See the source version on

About Norma Wade

Check Also

European stocks slide 2.8% after weak eurozone data and new UK economic plan

European stocks were down sharply on Friday as investors digested a series of central bank …